Stockscreener 앱 받기
1.88
1.33%
0.00
전일 마감가:
$1.88
열려 있는:
$1.91
하루 거래량:
866.60K
Relative Volume:
1.47
시가총액:
$86.89M
수익:
$19.94M
순이익/손실:
$-37.37M
주가수익비율:
-1.8077
EPS:
-1.04
순현금흐름:
$-33.38M
1주 성능:
-0.78%
1개월 성능:
+39.05%
6개월 성능:
+164.69%
1년 성능:
+3.53%
1일 변동 폭
$1.845
$1.9371
1주일 범위
$1.82
$2.15
52주 변동 폭
$0.595
$4.18
웨어울프 테라 Stock (HOWL) Company Profile
명칭
Werewolf Therapeutics Inc
전화
617-952-0555
주소
200 TALCOTT AVENUE, WATERTOWN
HOWL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.90 | 85.97M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
415.50 | 107.98B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.33 | 59.07B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.48 | 59.76B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.14 | 49.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
336.58 | 38.56B | 4.56B | -176.77M | 225.30M | -1.7177 |
웨어울프 테라 Stock (HOWL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-03 | 개시 | JMP Securities | Mkt Outperform |
| 2023-08-24 | 개시 | Wedbush | Outperform |
| 2023-06-06 | 재개 | Jefferies | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-25 | 개시 | Evercore ISI | Outperform |
| 2021-05-25 | 개시 | H.C. Wainwright | Buy |
| 2021-05-25 | 개시 | Jefferies | Buy |
| 2021-05-25 | 개시 | SVB Leerink | Outperform |
모두보기
웨어울프 테라 주식(HOWL)의 최신 뉴스
How high can Werewolf Therapeutics Inc. stock goEarnings Summary Report & Reliable Intraday Trade Alerts - newser.com
Werewolf Therapeutics receives FDA Fast Track for melanoma therapy By Investing.com - Investing.com Nigeria
Werewolf Therapeutics Says Investigational Melanoma Therapy WTX-124 Receives US FDA Fast Track Designation - MarketScreener
Werewolf Therapeutics receives fast track designation from the U.S. FDA for WTX-124, an investigational therapy for the treatment of cancer - MarketScreener
Werewolf Therapeutics Receives Fast Track Designation from - GlobeNewswire
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - Stock Titan
Werewolf Therapeutics Faces Nasdaq Compliance Challenge - TipRanks
Werewolf Therapeutics notifies Nasdaq of audit committee noncompliance after board member’s passing - Investing.com
Using flow based indicators on Werewolf Therapeutics Inc.Market Growth Summary & Risk Managed Trade Strategies - newser.com
Will earnings trigger a reversal in Werewolf Therapeutics Inc.2025 Institutional Moves & Long-Term Safe Investment Ideas - newser.com
Werewolf Therapeutics Inc. stock chart pattern explainedWeekly Trade Report & AI Enhanced Trade Execution Alerts - newser.com
Intraday pattern recognizer results for Werewolf Therapeutics Inc.Fed Meeting & Weekly High Return Stock Forecasts - newser.com
Will Werewolf Therapeutics Inc. stock maintain dividend yieldJuly 2025 Short Interest & Verified High Yield Trade Plans - newser.com
Jefferies Initiates Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $4 - 富途牛牛
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - GlobeNewswire
Werewolf Therapeutics to Present Innovative Research at SITC 40th Annual Meeting - Quiver Quantitative
3 Posters: Werewolf Therapeutics to Present WTX-124, mWTX-330 Research at SITC Nov 5-9 - Stock Titan
Published on: 2025-09-30 05:19:05 - newser.com
Goldman Sachs Group Inc. Has $109,000 Stock Holdings in Werewolf Therapeutics, Inc. $HOWL - Defense World
Published on: 2025-09-30 01:50:53 - newser.com
What analysts say about Werewolf Therapeutics Inc stockMomentum Trading Signals & Outstanding Growth Stocks - earlytimes.in
Earnings visualization tools for Werewolf Therapeutics Inc.Portfolio Performance Summary & Fast Moving Stock Trade Plans - newser.com
What institutional flow reveals about Werewolf Therapeutics Inc.Market Risk Analysis & Risk Controlled Swing Alerts - newser.com
웨어울프 테라 (HOWL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.91%
1.10%
자본화:
|
볼륨(24시간):